RE
TRIB

RBC Europe’s Trinity Biotech TRIB Stock Holding History

RBC Europe’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-158
Closed -$4.08K – 1179
2018
Q1 		$4.08K Hold
158
– – ﹤0.01% 983
2017
Q4 		$4.04K Hold
158
– – ﹤0.01% 991
2017
Q3 		$4.44K Buy
+158
New +$4.41K ﹤0.01% 968

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return

RBC Europe's TRIB Position: Q2 2018 in Review

RBC Europe sold out of Trinity Biotech (TRIB) in Q2 2018, closing a stake of 158 shares — an estimated $4.08K sold.

RBC Europe first reported a position in TRIB in Q3 2017 and held it in 3 quarters. The position peaked at $4.44K in Q3 2017. 45 funds tracked by Wall St. Rank hold TRIB as of Q2 2018.

  • RBC Europe reported no remaining Trinity Biotech position as of Q2 2018 after selling out during the quarter.
  • RBC Europe sold 158 Trinity Biotech shares in Q2 2018, an estimated $4.08K.
  • RBC Europe first reported a position in Trinity Biotech in Q3 2017 and held it in 3 quarters.
  • RBC Europe's Trinity Biotech position peaked at $4.44K in Q3 2017.
  • 45 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2018.

Based on RBC Europe's 13F filing for Q2 2018, filed 9 Nov 2023.